文献速递甲状腺疾病

RAS突变在术前细针活检中用于甲状腺结节管理决策的价值:单中心前瞻性队列研究结果

Utilities of RAS Mutations in Preoperative Fine Needle Biopsies for Decision Making for Thyroid Nodule Management: Results from a Single-Center Prospective Cohort.
PubMed 文献 · Thyroid · 2020-02-20

2015年2月至2017年12月波士顿医学中心连续1400例甲状腺活检中,546例细针活检用ThyroSeq二代测序检测RAS突变。504例获得分子信息,173例有分子改变,80例RAS阳性。56例RAS阳性结节手术,33例(58.9%)良性,7例(12.5%)为NIFTP,16例(28.6%)为甲状腺癌。RAS单独突变在Bethesda III/IV细胞学中鉴别恶性阳性预测值25.5%、阴性预测值89.7%、准确率54.0%(NIFTP不计为癌)。

要点

  • RAS突变占本系列全部分子改变的46.2%,为最常见遗传学改变。
  • RAS单独突变在Bethesda III/IV细胞学中鉴别恶性阳性预测值25.5%、阴性预测值89.7%、准确率54.0%。
  • 12例经组织学证实RAS单独阳性的恶性结节均呈低危特征和良好预后。

核心结论

  • RAS突变是本系列中最常检测到的遗传学改变;RAS单独突变在Bethesda III/IV细胞学中无助于识别恶性,但可能预测良好生物学行为,故应考虑用于指导初始管理。

研究设计与样本

  • 单中心前瞻性队列研究,2015年2月至2017年12月在波士顿医学中心连续行1400例甲状腺活检,其中546例细针活检用ThyroSeq二代测序面板评估RAS突变,RAS阳性结节前瞻性随访并收集病历。

主要发现

  • ThyroSeq在504个结节中成功提供分子信息,173个有分子改变,80个为Kirsten-RAS、Neuroblastoma-RAS或Harvey-RAS基因突变阳性;RAS基因突变占全部分子改变的46.2%。
  • 80个RAS阳性结节中56个接受手术,33个(58.9%)证实为良性,7个(12.5%)为非浸润性滤泡性甲状腺肿瘤伴乳头状核特征(NIFTP),16个(28.6%)为甲状腺癌。
  • 在细胞学不确定结节中,NIFTP不计为癌时,RAS突变识别恶性的阳性预测值为25.5%、阴性预测值为89.7%、准确率为54.0%。
  • RAS与其他突变合并增加恶性风险;12个经组织病理学证实的RAS单独阳性恶性结节均显示低危特征和良好预后。
  • 在本系列中,RAS亚型对预测恶性和治疗反应帮助甚微。

临床怎么用

  • 作者认为RAS单独突变在Bethesda III/IV细胞学中无助于识别恶性,但可能预测良好行为,故应考虑用于指导初始管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: It has been advocated to apply individualized strategies to evaluate thyroid nodules due to the growing awareness that the pathogenesis of thyroid cancer is not uniform. Molecular markers in fine needle biopsies (FNBs) may be helpful for the diagnosis and management decisions. Unlike the detection of BRAF mutations, the clinical utility of rat sarcoma viral oncogene homolog (RAS) mutations has not been fully elucidated. This study aimed at presenting a real-world performance of RAS mutations in identifying thyroid malignancies, at investigating the nature of thyroid tumors carrying RAS mutations, and at providing an additional reference for interpreting how to utilize the presence of RAS mutations in the decision-making process of thyroid nodule management. Methods: Between February 2015 and December 2017, 1400 sequential thyroid biopsies were performed at Boston Medical Center. Of these, 546 FNBs were evaluated for RAS mutations by using a ThyroSeq next-generation sequencing panel. Nodules carrying RAS mutations were prospectively followed, and medical records were collected. Results: ThyroSeq successfully provided molecular information in 504 nodules; 173 with molecular alteration(s); and 80 positive for mutations in the Kirsten-, Neuroblastoma-, or Harvey-RAS genes. RAS gene mutations constituted up to 46.2% of the total molecular alterations found in the study. Fifty-six of the 80 RAS-positive nodules underwent surgery, 33 (58.9%) were confirmed to be benign, 7 (12.5%) were noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP), and 16 (28.6%) were thyroid carcinomas. The positive predictive value, negative predictive value, and accuracy of RAS mutations for identifying malignancies among cytologically indeterminate nodules were 25.5%, 89.7%, and 54.0% when NIFTP was not counted as cancer. A combination of RAS and other mutations increased the risk of malignancy. Twelve histopathologically proved RAS-only-positive malignant nodules all showed low-risk features and favorable prognosis. RAS isoforms added little assistance for predicting a malignancy and the response to therapy in our series. Conclusions:RAS mutations represent the most frequently detected genetic alterations in our series. RAS mutations, when occurring alone, are not helpful markers to identify malignancy among Bethesda III/IV cytologies, but may predict favorable behavior, and hence should be considered to guide initial management.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Guan H, Toraldo G, Cerda S, et al. Utilities of RAS Mutations in Preoperative Fine Needle Biopsies for Decision Making for Thyroid Nodule Management: Results from a Single-Center Prospective Cohort. Thyroid. 2020. PMID: 31996097. doi:10.1089/thy.2019.0116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。